Dr. Dan P. Zandberg
Claim this profileUniversity of Pittsburgh Cancer Institute (UPCI)
Expert in Thyroid Cancer
Expert in Squamous Cell Carcinoma
20 reported clinical trials
36 drugs studied
Area of expertise
1Thyroid Cancer
Global LeaderStage IV
Stage III
p16 positive
2Squamous Cell Carcinoma
Global LeaderStage IV
Stage III
PD-L1 positive
Affiliated Hospitals
Clinical Trials Dan P. Zandberg is currently running
Pembrolizumab + Radiation vs Chemotherapy + Radiation
for Head and Neck Cancer
This phase II trial studies the effect of pembrolizumab alone compared to the usual approach (chemotherapy \[cisplatin and carboplatin\] plus radiation therapy) after surgery in treating patients with head and neck squamous cell carcinoma that has come back (recurrent) or patients with a second head and neck cancer that is not from metastasis (primary). Radiation therapy uses high energy radiation or protons to kill tumor cells and shrink tumors. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of cancer cells. Carboplatin is also in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer and may interfere with the ability of tumor cells to grow and spread. Giving pembrolizumab alone after surgery may work better than the usual approach in shrinking recurrent or primary head and neck squamous cell carcinoma.
Recruiting1 award Phase 231 criteria
Targeted Therapy vs. Chemotherapy
for Thyroid Cancer
This phase III trial compares the effect of cabozantinib versus combination dabrafenib and trametinib for the treatment of patients with differentiated thyroid cancer that does not respond to treatment (refractory) and which expresses a BRAF V600E mutation. Cabozantinib is in a class of medications called receptor tyrosine kinase inhibitors. It binds to and blocks the action of several enzymes which are often over-expressed in a variety of tumor cell types. This may help stop or slow the growth of tumor cells and blood vessels the tumor needs to survive. Dabrafenib is an enzyme inhibitor that binds to and inhibits the activity of a protein called B-raf, which may inhibit the proliferation of tumor cells which contain a mutated BRAF gene. Trametinib is also an enzyme inhibitor. It binds to and inhibits the activity of proteins called MEK 1 and 2, which play a key role in activating pathways that regulate cell growth. This may inhibit the growth of tumor cells mediated by these pathways. The usual approach for patients with thyroid cancer is targeted therapy with dabrafenib and trametinib. This trial may help researchers decide which treatment option (cabozantinib alone or dabrafenib in combination with trametinib) is safer and/or more effective in treating patients with refractory BRAF V600E-mutated differentiated thyroid cancer.
Recruiting2 awards Phase 37 criteria
More about Dan P. Zandberg
Clinical Trial Related3 years of experience running clinical trials · Led 20 trials as a Principal Investigator · 11 Active Clinical TrialsTreatments Dan P. Zandberg has experience with
- Cisplatin
- Nivolumab
- Carboplatin
- Pembrolizumab
- Ipilimumab
- Docetaxel
Breakdown of trials Dan P. Zandberg has run
Thyroid Cancer
Squamous Cell Carcinoma
Head and Neck Squamous Cell Carcinoma
Relapse
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Dan P. Zandberg specialize in?
Dan P. Zandberg focuses on Thyroid Cancer and Squamous Cell Carcinoma. In particular, much of their work with Thyroid Cancer has involved Stage IV patients, or patients who are Stage III.
Is Dan P. Zandberg currently recruiting for clinical trials?
Yes, Dan P. Zandberg is currently recruiting for 11 clinical trials in Pittsburgh Pennsylvania. If you're interested in participating, you should apply.
Are there any treatments that Dan P. Zandberg has studied deeply?
Yes, Dan P. Zandberg has studied treatments such as Cisplatin, Nivolumab, Carboplatin.
What is the best way to schedule an appointment with Dan P. Zandberg?
Apply for one of the trials that Dan P. Zandberg is conducting.
What is the office address of Dan P. Zandberg?
The office of Dan P. Zandberg is located at: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania 15232 United States. This is the address for their practice at the University of Pittsburgh Cancer Institute (UPCI).
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.